Mesoblast Limited Sponsored ADR Stock
Mesoblast Limited Sponsored ADR Stock price
Key metrics
| Market capitalization | $1.47b |
| Enterprise Value | $1.56b |
| P/E (TTM) P/E ratio | negative |
| EV/FCF (TTM) EV/FCF | negative |
| EV/Sales (TTM) EV/Sales | 275.76 |
| P/S ratio (TTM) P/S ratio | 260.20 |
| P/B ratio (TTM) P/B ratio | 2.88 |
| Revenue (TTM) Revenue | $5.66m |
| EBIT (operating result TTM) EBIT | $-51.63m |
Is Mesoblast Limited Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.
Mesoblast Limited Sponsored ADR Stock Analysis
Analyst Opinions
6 Analysts have issued a Mesoblast Limited Sponsored ADR forecast:
Analyst Opinions
6 Analysts have issued a Mesoblast Limited Sponsored ADR forecast:
Financial data from Mesoblast Limited Sponsored ADR
| Dec '24 |
+/-
%
|
||
| Revenue | 5.66 5.66 |
27%
27%
|
|
| Gross Profit | 9.38 9.38 |
150%
150%
|
|
| EBITDA | -47 -47 |
-
|
EBIT (Operating Income) EBIT | -52 -52 |
29%
29%
|
| Net Profit | -103 -103 |
26%
26%
|
|
In millions USD.
Don't miss a Thing! We will send you all news about Mesoblast Limited Sponsored ADR directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Mesoblast Limited Sponsored ADR Stock News
Company Profile
Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target the cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Itescu Silviu on June 8, 2004 and is headquartered in Melbourne, Australia.
| Head office | Australia |
| CEO | Silviu Itescu |
| Employees | 73 |
| Founded | 2004 |
| Website | www.mesoblast.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
